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The expression of 5-lipoxygenase (5-LOX) is aﬀected by aging and regulated by epigenetic mechanisms including DNA
methylation. We used methylation-sensitive restriction endonucleases (AciI, BstUI, HpaII, and HinP1I) to assess 5-LOX DNA
methylationinbrainandhearttissuesamplesfromyoung(2months)andold(22months)mice.WealsomeasuredmRNAcontent
for 5-LOX and the DNA methyltransferases DNMT1 and DNMT3a. In young mice, the 5-LOX mRNA content was signiﬁcantly
greater in the heart compared to the brain; 5-LOX DNA methylation was lower, except in the AciI assay in which it was higher
in the heart. Aging decreased 5-LOX mRNA content in the heart and increased it in the brain. Aging also increased 5-LOX DNA
methylation and this eﬀect was site- (i.e., enzyme) and tissue-speciﬁc. Generally, DNMT1 and DNMT3a mRNA content was lower
in the brain regions compared to the heart; the only eﬀect of aging was observed in the mRNA content of DNMT3a, which was
decreased in the heart of old mice. These results indicate a complex tissue-speciﬁc and aging-dependent interplay between the
DNA methylation system and 5-LOX mRNA content. Interpretation of this data must take into account that the tissue samples
contained a mixture of various cell types.
Copyright © 2009 Svetlana Dzitoyeva et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
5-lipoxygenase (5-LOX; EC 1.13.11.34; encoded by the
ALOX5 gene) is the key enzyme in the biosynthesis of lipid
signaling molecules, that is, the inﬂammatory leukotrienes
andtheanti-inﬂammatorylipoxins [1,2].The5-LOXsystem
is considered one of the key players in inﬂammation [3], an
importantpathwayinthecardiovascularsystem(particularly
in atherosclerosis) [4, 5], and a putative modulator of central
nervous system (CNS) functioning and pathobiology [6–
8]. Moreover, the 5-LOX pathway has been considered in
mechanisms of neural plasticity ranging from neurogenesis
and neural diﬀerentiation [9] to regulation of synaptic
plasticity [10, 11]. For example, metabolites derived from 5-
LOX activity have been implicated in the expression of long-
term depression in hippocampal slices [10].
It is believed that a nonleukocyte synthesis of leu-
kotrienes does not require 5-LOX and that in the CNS and
in the heart, leukotrienes can be produced via a transcellular
biosyntheticpathway[12,13].Nevertheless,thereisevidence
for 5-LOX expression in these organs/systems [6, 14–
16]. Thus, regulation of the brain expression of 5-LOX
participates in mechanisms of neuroprotection [8]. In the
CNS of rats and mice, 5-LOX expression increases during
aging [14, 17] and in brain ischemia [18, 19]. In the human
brain, 5-LOX protein content is elevated in Alzheimer’s
disease [7, 20] and in response to ischemia [21]. In the
heart,5-LOXcontentappearstoremainstableduringcardiac
remodeling [16] but can be altered by dietary modiﬁcations
[22]. Furthermore, in the heart, that is, myocardial cells,
drugs such as statins and thiazolidinediones trigger anti-
inﬂammatory processes and increase the production of anti-
inﬂammatory lipoxins depending on 5-LOX, particularly the
status of 5-LOX phosphorylation [15, 23].
5-LOX gene expression is regulated by epigenetic mech-
anisms including modiﬁcations of DNA methylation [1, 24–
26]. Epigenetics encompasses the modiﬁcation of chromatin
structure that leads to regulation of the gene expression and2 Neural Plasticity
Table 1: Primer sequences used to assay 5-LOX, DNMT1, DNMT3a, and cyclophilin (reference) mRNA.
mRNA Gene bank
accessio number
Primers Fragment size (bp)
5-LOX NM 009662
F: 5 -ATTGCCATCCAGCTCAACCAAACC-3 
178
R: 5 -TGGCGATACCAAACACCTCAGACA-3 
DNMT1 NM 010066 F: 5 -AGTGCAAGGCGTGCAAAGATATGG-3 
150
R: 5 -TGGGTGATGGCATCTCTGACACAT-3 
DNMT3a NM 007872 F: 5 -ACAAGAATGCTACCAAAGCAGCCG -3 
200
NM 153743 R: 5 -TGAGAACTTGCCATCTCCGAACCA-3 
Cyclophilin X52803
F: 5 - AGCATACAGGTCCTGGCATCTTGT –3 
153
R: 5 - AAACGCTCCATGGCTTCCACAATG -3 
phenotype. Epigenetic modiﬁcations are further inﬂuenced
by the environment (“life experience”) and are typically
long lasting and sometimes heritable. Recently, epigenetic
mechanisms have been implicated in the pathobiology of
psychiatric disorders [27]. Thus, DNA methylation at the
sites of CpG dinucleotides has been implicated in gene
regulation in virtually all tissues, including the brain [28].
Siegmund et al. [28] studied human cerebral cortex samples
in aging subjects and found a progressive aging-associated
rise in the DNA methylation of 5  CpG islands of certain
CNS genes, typically in conjunction with declining levels of
their corresponding mRNAs. These authors concluded that
DNA methylation is dynamically regulated in the human
cerebral cortex throughout the lifespan, involves diﬀeren-
tiated neurons, and aﬀects a substantial portion of genes
predominantly by an age-related increase. In addition, data
are available on epigenetic mechanisms and cardiovascular
gene regulation. For example, it was observed that the
genomic DNA methylation in patients with coronary artery
disease is signiﬁcantly higher than in controls [29].
It has been hypothesized that the 5-LOX pathway
may be involved in the comorbidity of certain heart and
brain disorders [30, 31]. Furthermore, it was proposed
that comparative studies of heart and brain tissues from
the same subjects would improve eﬀorts in this area of
research [32]. Here, we investigated whether aging aﬀects
brain and heart 5-LOX mRNA levels and DNA methylation.
Because mice are used in many 5-LOX-related experimental
models, including 5-LOX-deﬁcient mice, we investigated
mouse tissue samples. However, a conundrum of epigenetic
research of CNS- and heart-expressed genes lies not only
in the cell-speciﬁcity of epigenetic mechanisms, but also in
their species-speciﬁcity. Thus, the human 5-LOX gene is on
chromosome 10, whereas in the mouse it is on chromosome
6. Comparing the DNA regions of the 5-LOX promoter and
exon1(1844nt,human;1937nt,mouse),wefound132CpG
dinucleotides in the human and only 59 in the mouse gene
promoter regions. To study the methylation status of this
region, we employed our recently developed methylation-
sensitive restriction endonuclease assay [33]. Since DNA
methylation depends on DNA-methyltransferases (DNMTs),
we investigate the tissue content of mRNAs for DNMT1
and DNMT3a, the maintenance, and the de novo DNMTs,
respectively [34].
2.MaterialandMethods
2.1. Tissue Samples. Two-month-old (young) and 22-
month-old (old) C57BL/6J male mice were obtained from
the National Institute on Aging (Bethesda, MD). They
were housed in groups of 4–6 in a temperature controlled
room and had free access to laboratory chow and water.
Cerebellum, frontal cortex, hippocampus, and heart (the
apex portion was selected as a source of uniform ventric-
ular myocytes [35]) tissues were obtained following lethal
anesthesia (160mg/kg ketamine; Sigma, St. Louis, MO) and
transcardial perfusion with 0.9% ice-cold saline to remove
the circulating blood cells (i.e., until the outﬂow from the
right atrium was clear). The experimental protocol was
approved by the Institutional Animal Care Committee.
2.2. RNA Isolation and Real-Time PCR (qPCR). The total
RNA was extracted using the chemical isolation method
with TRIzol reagent (Invitrogen, Carlsbad, CA) following
the manufacturer’s instructions. To eliminate possible DNA
contamination, RNA samples were treated with a DNase
reagent, DNA-free (Ambion, Inc., Austin, TX). Total RNA
(3µg) was reverse transcribed with 200U of cloned Moloney
Murine Leukemia Virus (M-MLV) reverse transcriptase
(Gibco BRL, Carlsbad, CA). The qPCR was performed
in a Stratagene Mx3005P QPCR System (Stratagene, La
Jolla, CA) using Maxima SYBR Green qPCR Master Mix
(Fermentas,GlenBurnie,MD)inatwo-stepcyclingprotocol
as described by the manufacturer. There was an initial 5
minutes denaturing followed by 40 cycles of denaturing at
95◦C for 15 seconds and annealing/elongation at 60◦Cf o r
1m i n u t e .Table 1 shows primer sequences used to detect 5-
LOX, DNMTs, and cyclophilin mRNAs (primers were pur-
chased from Integrated DNA Technologies, Inc., Coralville,
IA). For validation purposes, the ampliﬁcation products of
all above-noted genes were run on agarose gels. For each
product, we obtained one single band of the expected size
(data not shown). Furthermore, the 5-LOX PCR product
was veriﬁed by sequencing. Reactions were performed using
three diﬀerent concentrations (12.5, 25, 50ng) of reverse
transcribed material (in duplicate for each sample). The
qPCR results were normalized against the corresponding
cyclophilin contents. Data are presented in units calculated
as a coeﬃcient of variation 2−[Ct (target) − Ct (input)] [36].Neural Plasticity 3
GGCAGAGGAACAAGGGCTTCAGCCTATCAGAGATCACTGTCCCTCCAGTGCCACAGGAGA
GAAGGATGCGTTGGAAGGTGGGGTCCTGGGACTGGCCAGAGACAGGGGCGGAGCCAGCGC
CTGAAGGCAGGGCCGGTCGCAGGGTGGAGCCAGACCCAAGCGCAAGGCTGGCCCGCTGCT
GGCCACTGTGGCAGGGAGCTGCCGCGAGTGACAGGGTCAAGAAGTTGGTGGGCTGCCACG
CCGAGCTTCGCGGGCTCCTGCTCCCACACCAGCAGCACTCACTTGCCCGGAGTCATGCCC
TCCTACACGGTCACCGTGGCCACCGGCAGCCAGTGGTTCGCGGGCACCGACGACTACATC
TACCTCAGCCTCATTGGCTCTGCGGGCTGTAGCGAGAAGCATCTGCTGGACAAGGCATTC
TACAATGACTTCGAACGGGGCGCGGTGAGAATGCGCGCTTGGGACCGACGGCTGGCAGCA
GGGAGGGCGGCGGGGCAGGACAGGCAGGCACCTGAGAACTGTCTGTCCAAGAGCCAGCGCG
CTCGTGACCCTATGTGAGCGCATCTGGGGATCTGATGCAGCGCCAGAGTCGGTGCATGCC
AGGGCAAGCGAGGCACCCTAGACTTCCTGATGACTCGGGTATCTTAAGGGACA
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Figure 1: The sequence of the mouse 5-LOX promoter-5  UTR and the ﬁrst exon-intron region subjected to the methylation-sensitive
endonuclease assay with the four endonucleases—AciI, BstUI, HinP1I, and HpaII. The yellow highlight indicates the ﬁrst exon including
the start codon (ATG, in red). The four endonuclease-targeted methylation-sensitive endonuclease recognition sites are highlighted by four
diﬀerent colors. The selected DNA sequence included 2 AciI-sensitive sites (upstream of the start codon), 6 BstUI-sensitive sites (2 upstream
and4downstreamof thestartcodon),8HinP1I-sensitivesites(2upstream and6downstreamof thestartcodon),and3HpaII-sensitivesites
(2upstreamand1downstreamofthestartcodon).TheprimerregionsusedforquantitativePCRampliﬁcationareunderlined;primerswere
used as follows. Promoter - 5  UTR: forward = 5 -aga gaa gga tgc gtt gga aggt-3  and reverse = 5 -gac tcc ggg caa gtg agt gct-3 ; exon-intron:
forward = 5 -agt cat gcc ctc cta cac ggt ca-3  and reverse = 5 -agt cat gcc ctc cta cac ggt ca-3 . For the input control, we used the following
primers: forward = 5 -tga tgt ggc tgg cct ctt atg tga-3 ,r e v e r s e= 5 -act ggg act gag tgc agg aaa tgt-3 .
2.3. 5-LOX DNA Methylation Assay. Genomic DNA was
extracted from the above-noted tissues. They were homog-
enized in homogenizing buﬀer (100mM NaCl, 10mM Tris-
HCl pH 8.0, 25mM EDTA, 0.5% SDS, 0.1mg/ml proteinase
K), 100µl per 10mg of tissue, and incubated 4-5 hours
at 37◦C. The DNA was puriﬁed with phenol, phenol-
chloroform (pH 8.0), precipitated with isopropanol, and
dissolved in H2O. The DNA methylation assay was designed
as follows: The promoter-exon-intron structure of the Mus
musculus 5-LOX gene was reconstructed by aligning the
5-LOX (ALOX5) mRNA (NM 009662), the promoter, the
5  untranslated region (UTR), and partial coding region
sequences (AF393814) with the mouse genome sequence.
This procedure identiﬁed a sequence of about 53kb.
Although the mouse 5-LOX gene promoter does not contain
typicalCpGislands,themouse5-LOXpromoter-5 UTR-ﬁrst
exon, the adjacent intron portion, and the 3  e n do ft h eg e n e
contain the highest C and G densities. The 5 UTR-ﬁrst exon
and the adjacent intron region (comprising 519 nucleotides)
contain 66% of all C and G nucleotides. Furthermore,
this region contains 41CpG dinucleotides; 14 are located
upstream from the ATG translation start codon and 27
are downstream (Figure 1). Multiple methylation-sensitive
endonuclease recognition sites were located in that portion.
Thus, we investigated their methylation rate (i.e., upstream
and downstream from the ATG translation start codon) with
the aid of four methylation-sensitive endonucleases—AciI
(C ↓ CGC), BstUI (CG ↓ CG), HinP1I (G ↓ CGC), and
HpaII (C ↓ CGG) (their respective recognition sequences
cutting sites are shown in parentheses). To measure the
5-LOX DNA methylation levels, we used the restriction
digest-quantitative PCR (SYBR Green RD-qPCR). The
selected approach utilizes the ability of methylation-sensitive
endonucleases to digest only unmethylated recognition sites,
and their inability to act on sites with methylated cytosine.
Thus, if the targeted ∗CpG is methylated, the site is blocked
for the enzyme’s endonuclease activity and as a result,
greater amounts of templates are available for the action
of the Taq DNA polymerase. The assay was performed as
follows: 1µg of genomic DNA was used in a restriction
digest reaction for each of the four endonucleases. Digested
DNA samples were diluted with water and an aliquot (100ng
DNA) was used for qPCR (Stratagene) with the Maxima
SYBR Green qPCR Master Mix (Fermentas) according to
the manufacturer’s protocol. The following primers were
used: forward 5 -agagaaggatgcgttggaaggt-3  and reverse 5 -
gactccgggcaagtgagtgct -3 . These primers amplify the 238nt
regionupstreamoftheﬁrstATGtranslationstartcodon.This
region contains two recognition sites for each of 4 endonu-
cleases selected for the assay. Primers for the exon-intron
part were as follows: forward 5 -agtcatgccctcctacacggtca-
3 , reverse 5 -agtcatgccctcctacacggtca-3 . They amplify a
344bp fragment. For the input control, we used the 394nt
region in the ﬁrst intron because this region does not con-
tain recognition sites for the selected methylation-sensitive
endonucleases. This region was ampliﬁed with the following
primers: forward 5 -tgatgtggctggcctcttatgtga-3 , reverse 5 -
actgggactgagtgcaggaaatgt-3 . The qPCR reactions were run
with 2 diﬀerent primer sets (target and input) in separate
tubes and the coeﬃcient of variation for the relative amount
of a target sequence was calculated [36]. An example of the
qPCR assay performance is shown in Figure 2.
2.4. Statistics. For statistical analysis, we used SPSS soft-
ware (version 12.0). Data were analyzed by either one-way
ANOVA followed by Dunnett’s multiple comparison test, or4 Neural Plasticity
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Figure 2: An example of the SYBR Green RD-qPCR assay of 5-LOX DNA methylation (shown are graphs obtained from 10 cerebellar
samples). The samples were digested with the methylation-sensitive endonucleases (AciI, BstUI, HinP1I, and HpaII) as described in Material
and Methods. The PCR reaction for the promoter-5 U T R( 1 0s a m p l e se a c h :A c i I= blue, BstUI = red, HinP1I = green, and HpaII = gray) and
corresponding input control regions (shown in yellow) were carried out in separate tubes. Panel A shows the dissociation curve data, which
indicate the presence of only one PCR product (peak) for each speciﬁc set of primers (ﬂuorescence (ﬁrst derivative of the raw ﬂuorescence
reading multiplied by −1) on the Y-axis versus the PCR product melting temperature (◦C) on the X-axis). Panel B shows examples of the
ampliﬁcation plots used for calculating the quantitative data (the ampliﬁcation plots ﬂuorescence (baseline-corrected raw ﬂuorescence) on
the Y-axis versus cycle number on the X-axis). In this assay, the threshold cycle is inversely proportional to the log of the initial copy number.
In other words, the more template that is present initially, the fewer the number of cycles required for the ﬂuorescence signal to be detectable
above background.Neural Plasticity 5
Heart Cerebellum Frontal
cortex
Hippocampus
0
1
30
40
50
5
-
L
O
X
m
R
N
A
(
u
n
i
t
s
) ∗
∗∗
∗
Young
Old
Figure 3: 5-LOX mRNA levels in heart and brain tissues of young
and old mice. The content of 5-LOX mRNA in the tissues of young
(2-month-old, open bars) and old (22-month-old, closed bars)
mice was measured by real-time PCR. The results were normalized
against the corresponding cyclophilin mRNA contents and are
presented as units (the coeﬃcient of variation values ampliﬁed by
a factor of 1000, see text for details). Data are expressed as mean
± S.E.M (n = 5 − 10); ∗P<. 05 and ∗∗P<. 01 versus the
corresponding values in young (t-test).
by an independent sample t-test. Results are expressed as the
mean ±S.E.M.from5to10animals.TheP<. 05valueswere
accepted as statistically signiﬁcant.
3. Results
Figure 3 shows that the expression levels of 5-LOX mRNA
in heart tissue are about ﬁfty times greater than in brain
tissue. Similar to previously published data, we found that
during aging, 5-LOX content in the brain (e.g., cerebellum
and frontal cortex) increases. However, in the heart, aging
resulted in signiﬁcantly decreased 5-LOX mRNA levels
(Figure 3).
Using the 5-LOX DNA methylation assay, which is
based on the ability of methylation-sensitive endonucleases
to digest only unmethylated recognition sites, we found
that the four endonucleases—AciI, BstUI, HinP1I, and
HpaII—revealed a diﬀerential tissue- and brain-region-
speciﬁc methylation status of 5-LOX DNA (Figure 4). The
DNA region targeted by AciI was more methylated in the
heart compared to the brain; whereas the DNA regions
targeted by BstUI, HinP1I, and HpaII were more methylated
in the brain (frontal cortex and hippocampus but not the
cerebellum) than in the heart (Figure 4). Aging generally
increased 5-LOX DNA methylation but this eﬀect was
diﬀerential with respect to the DNA region studied, the type
of the tissue/organ (e.g., heart versus brain), and the brain
region we investigated. Focusing on the promoter-5 UTR
region (Figure 4), we found the eﬀect of aging in the areas
targeted by AciI, BstUI, and HpaII but not HinP1l. Thus, the
methylation levels assayed by AciI and BstUI were increased
by aging in all tissues studied, whereas the methylation levels
studied by HpaII were increased only in the hippocampus.
Focusing on the exon-intron region, we found that aging
increased methylation only in the brain and only in the DNA
regionsensitivetoBstUI(unitsasinFigure 4(two-tailt-test);
frontal cortex: young = 110 ± 14, old = 163 ± 14, P<. 05,
n = 10; hippocampus: young = 86 ± 8, old = 136 ± 17,
P<. 05, n = 5; cerebellum: young = 36 ± 6, old = 58 ±
10, n.s., n = 5; heart: young = 42 ± 20, old = 54 ± 10; ns,
n = 5).
The content of mRNA for DNMT1and DNMT3a (main-
tenance and the de novo DNMTs, resp.) was generally greater
in the heart compared to the brain, particularly the content
of DNMT3a mRNA (Figure 5). The only aging-associated
diﬀerence we observed was the decreased DNMT3a mRNA
content in the heart of old versus young mice (Figure 5(b)).
4. Discussion
In line with previous reports [14], we conﬁrmed that 5-
LOX mRNA is expressed in the mouse brain, albeit at levels
signiﬁcantly lower than 5-LOX mRNA levels measured in
heart tissue. We also conﬁrmed that aging increases 5-LOX
mRNA content in the brain. In our previous work with rat
brain tissue, we found an aging-associated 5-LOX increase
in the cerebellum and the hippocampus [37]. In this study
with mice, we found an aging-associated 5-LOX increase
in the cerebellum and the frontal cortex but not in the
hippocampus. These diﬀerences do not appear to be species-
related (e.g., rat versus mouse) because others found that
agingincreases5-LOXexpressioninthemousehippocampus
but not in the cerebellum and cortex [14]. The reason for
these discrepancies is not apparent, but considering the
putative epigenetic regulation of 5-LOX expression, it is
likely that individual life experiences of various colonies of
old rodents could result in a colony-speciﬁc aging-modiﬁed
epigenetic regulation of 5-LOX expression. Regardless of
the observed regional diﬀerences, all previous studies [14,
17, 37] and our present results are consistent as to the
direction (i.e., increase) of aging-associated changes in brain
5-LOX expression. In contrast to the observed eﬀects of
aging in brain tissue, we found that in heart tissue aging
was associated with a decrease in 5-LOX mRNA content.
To our knowledge, this is the ﬁrst time that heart 5-LOX
expression has been investigated in the context of aging.
Previous studies reported that 5-LOX content in the heart
remains stable during cardiac remodeling [16]b u tc a nb e
altered by dietary modiﬁcations [22]. On the other hand, 5-
LOX protein content in the aorta was signiﬁcantly increased
in old (24 months) compared to adult (6 months) rats [38].
DNA methylation is an epigenetic mechanism involved
in the regulation of gene expression including the eﬀects
of aging and tissue-speciﬁc expression. We observed that in
the heart, which expresses about 50 times greater 5-LOX6 Neural Plasticity
Heart C FC H
0
200
400
600
5
-
L
O
X
D
N
A
m
e
t
h
y
l
a
t
i
o
n
(
u
n
i
t
s
)
∗
∗
∗∗
∗∗
AciI
(a)
Heart C FC H
0
40
80
120
5
-
L
O
X
D
N
A
m
e
t
h
y
l
a
t
i
o
n
(
u
n
i
t
s
)
∗∗
∗
∗∗
∗∗∗
BstUI
(b)
Heart C FC H
0
20
40
60
80
5
-
L
O
X
D
N
A
m
e
t
h
y
l
a
t
i
o
n
(
u
n
i
t
s
)
HinP1I
(c)
Heart C FC H
0
40
80
120
5
-
L
O
X
D
N
A
m
e
t
h
y
l
a
t
i
o
n
(
u
n
i
t
s
)
∗
HpaII
(d)
Figure 4: The eﬀect of aging on 5-LOX DNA methylation in the region promoter-5 UTR. The methylation-sensitive endonuclease assay
with the four endonucleases—AciI, BstUI, HinP1I, and HpaII—was performed as described in the text and indicated in Figure 1. The heart
and brain (C: cerebellum, FC: frontal cortex, H: hippocampus) tissue samples were obtained from 2-month-old mice (open bars) and 22-
month-old mice (closed bars). The results are expressed as units (the coeﬃcient of variation values multiplied by a factor of 1000, see text for
details) and shown as mean ± S.E.M (heart, C, and H: n = 5; FC: n = 10). ∗P<. 05, ∗∗P<. 01, and ∗∗∗P<. 001 versus the corresponding
values in samples from 2-month-old mice (t-test).
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Figure 5: DNMT1 (a) and DNMT3a (b) mRNA levels in heart and brain tissues of young and old mice. The content of DNMT1/DNMT3a
mRNA in the tissues of young and old mice was measured by real-time PCR. The results were normalized against the corresponding
cyclophilin mRNA contents and are presented as units (the coeﬃcient of variation values ampliﬁed by a factor of 1000, see text for details).
Data are expressed as mean ± S.E.M (n = 5−10). Note that the only aging-associated diﬀerence was observed for DNMT3a mRNA content
intheheart (#P<. 01,t-test).Thecontent ofDNMTmRNAwas generally greater intheheart compared tothebrain; ∗P<. 05and ∗P<. 001
versus the corresponding values in the heart in the same age group (Dunnett’s test).Neural Plasticity 7
mRNA levels than the brain, the DNA regions targeted by
BstUI, HinP1I, and HpaII were less methylated than those
in the brain. Typically, methylation of proximal promoters
containing a high density of CpG dinucleotides (CpG
islands) leads to long-term gene silencing.
Compared to human 5-LOX, the mouse 5-LOX DNA
sequence lacks the typical CpG islands. The methylation
status of the nonisland CpG loci appears to be equally rel-
evant for gene regulation [39]. For example, Sakamoto et al.
[40] reported that the tissue-dependently and diﬀerentially
methylated regions were disproportionately distributed in
the nonisland CpG loci and that these loci were located not
only in 5  regions of genes but also in intronic and nongenic
regions. The mouse 5-LOX promoter-5  UTR sequence has
an equal number (i.e., 2) of recognition sites for each of
the four endonucleases used in our assay. Nevertheless,
the eﬀect of aging on this 5-LOX DNA sequence was
extremely heterogeneous. For example, aging did not aﬀect
the methylation status assayed at the HinP1I sites, it only
aﬀected the HpaII sites in the hippocampus and produced
a similar eﬀect on AciI and BstUI sites in all tissue samples
studied. On the other hand, the exon-intron sequence has 4
BstUI, 6 HinP1I, 1 HpaII, and 1 AciI site. However, the only
eﬀect of aging in this 5-LOX DNA sequence was observed in
brain tissues and only in BstUI sites.
The pattern of DNA methylation depends on enzymes
such as DNMTs, in particular DNMT1 which is involved
in the maintenance of DNA methylation patterns and
DNMT3awhichpredominantlycontributestode-novoDNA
methylation. Senescence has been associated with alterations
in DNMT activity [41] and expression [28]. Although the
expression of DNMT1 and DNMT3a showed some tissue
and regional diﬀerences, we did not observe major aging-
associated alterations in the mRNA levels of these two
enzymes, with the only exception that there was lower
DNMT3a mRNA content in the heart of old mice. However,
this ﬁnding does not exclude the possibility of aging-altered
DNMT activity in the brain. Furthermore, multiple enzy-
matic mechanisms are involved in determining the pattern
of DNA methylation, including DNA-demethylases [42]. For
example, recent ﬁndings indicate that neuronal activity is
capable of triggering epigenetic DNA demethylation [43],
and it remains to be investigated whether this process is
aﬀected by aging and whether it could alter 5-LOX DNA
methylation in the absence of signiﬁcant DNMT changes.
Further research is needed to elucidate if the observed
changes in 5-LOX DNA methylation could play a role
in aging-associated modiﬁcations of tissue 5-LOX mRNA
levels. For such a functional role, DNA methylation status
would have to inﬂuence the binding of various methylation-
sensitive regulatory factors (e.g., transcription activators and
repressors). We subjected the 5-LOX DNA sequences used
in our assay (Figure 1) to an analysis with the software
for searching transcription factor binding sites (TFBIND),
whichusestheweightmatrixintranscriptionfactordatabase
TRANSFAC R.3.4. [44]. This analysis, along with the survey
of available literature, suggests that in the region upstream
of the mouse 5-LOX ATG start codon, the likely candidates
are the following transcription factors: AHR/ARNT, NMYC,
E2F, AP4, AP2, USF, and SP1. In the coding region, putative
regulatory factors include AHR/ARNT, USF, ELK1, HSF1,
H S F 2 ,A R P 1 ,R F X 1 ,G A T A 1 ,A P 4 ,E 2 F ,a n dA R P 1 .N e v e r -
theless, one must take into account that the tissue samples
we used in this study contained a mixture of cell types
and that the link between 5-LOX mRNA and 5-LOX DNA
methylation may depend on the cell type. Inherent in studies
with tissue samples as opposed to research in cell cultures is
that 5-LOX DNA extracted from tissue samples derives from
both 5-LOX mRNA-expressing and mRNA-nonexpressing
cells. This technical limitation negatively impacts the ability
to directly relate mRNA content and DNA methylation
status. Similarly, cell type may be decisive in determining
the type of 5-LOX metabolites produced (e.g., leukotrienes
versus lipoxins).
Although leukotriene synthesis in the CNS and in the
heart can occur via a transcellular biosynthetic pathway that
is believed not to require 5-LOX expression [12, 13], aging-
increased leukotriene synthesis in the hippocampus [14]a n d
aorta [38] appears to be associated with increased 5-LOX
expression. It was proposed that in the CNS, metabolites
derivedfrom5-LOXactivitycouldinﬂuenceneuralplasticity,
such as the expression of hippocampal long-term depression
[10]. Furthermore, it has been established that the biological
eﬀects of leukotrienes in the CNS [8]a n dh e a r t[ 23]c a n
be counteracted by noninﬂammatory 5-LOX metabolites
lipoxins. No data are available on the eﬀects of aging on
CNS and heart production of lipoxins. This information
appears necessary for a full understanding of the biological
implications of aging-altered expression of 5-LOX in the
brain and heart.
In conclusion, we found that in addition to altering
5-LOX mRNA content in heart and brain tissues, aging
increased 5-LOX DNA methylation, and also that this eﬀect
was DNA-site- and tissue-speciﬁc. It has to be stressed
that our results were obtained in tissue samples containing
a mixture of various cell types and that further insight
into functional implications of DNA methylation for 5-LOX
mRNA expression would require cell-type directed studies.
For example, one possibility is to focus on neuronal DNA in
braintissuesamplesbyapplyingmethodsforneuronalnuclei
isolation [45].
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